Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year

Written by Emily J. Thompson, Senior Investment Analyst

CKPT%

Updated: Mar 28 2025

0mins

FY24 Revenue Report: The company reported a revenue of $41,000 for FY24, a significant decrease from $103,000 in the previous year.
Year-over-Year Comparison: This marks a decline in financial performance compared to last year's figures.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Vistagen Therapeutics Faces Class Action Lawsuit with Deadline for Lead Plaintiff by March 16, 2026

Monero (XMR) Surges 44% in Five Days, Yet Investment Risks Persist

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch